JP2022542159A5 - - Google Patents
Info
- Publication number
- JP2022542159A5 JP2022542159A5 JP2022505338A JP2022505338A JP2022542159A5 JP 2022542159 A5 JP2022542159 A5 JP 2022542159A5 JP 2022505338 A JP2022505338 A JP 2022505338A JP 2022505338 A JP2022505338 A JP 2022505338A JP 2022542159 A5 JP2022542159 A5 JP 2022542159A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882297P | 2019-08-02 | 2019-08-02 | |
| US62/882,297 | 2019-08-02 | ||
| PCT/US2020/044553 WO2021026011A1 (en) | 2019-08-02 | 2020-07-31 | Solid-state forms of relugolix |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542159A JP2022542159A (ja) | 2022-09-29 |
| JPWO2021026011A5 JPWO2021026011A5 (https=) | 2023-08-01 |
| JP2022542159A5 true JP2022542159A5 (https=) | 2023-08-01 |
Family
ID=72145496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505338A Pending JP2022542159A (ja) | 2019-08-02 | 2020-07-31 | 固体形態レルゴリクス（Ｒｅｌｕｇｏｌｉｘ） |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230374030A1 (https=) |
| EP (1) | EP4007760A1 (https=) |
| JP (1) | JP2022542159A (https=) |
| KR (1) | KR20220047972A (https=) |
| CN (1) | CN114174302A (https=) |
| BR (1) | BR112022001002A2 (https=) |
| CA (1) | CA3145993A1 (https=) |
| WO (1) | WO2021026011A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12441738B2 (en) | 2018-03-14 | 2025-10-14 | Assia Chemical Industries Ltd. | Solid state forms of Relugolix |
| WO2021031148A1 (zh) * | 2019-08-21 | 2021-02-25 | 深圳仁泰医药科技有限公司 | 促性腺素释放激素拮抗剂的晶型及其制备方法和用途 |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| CN113620972A (zh) * | 2021-02-02 | 2021-11-09 | 奥锐特药业(天津)有限公司 | 瑞卢戈利新晶型及其制备方法 |
| CN114031626A (zh) * | 2021-12-09 | 2022-02-11 | 成都科圣原医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| WO2025037218A1 (en) * | 2023-08-11 | 2025-02-20 | Glenmark Life Sciences Limited | Crystalline solvate of relugolix and a process for its preparation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7300935B2 (en) * | 2003-01-29 | 2007-11-27 | Takeda Pharmaceutical Company | Thienopyrimidine compounds and use thereof |
| WO2010026993A1 (ja) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| AR092707A1 (es) * | 2012-09-28 | 2015-04-29 | Takeda Pharmaceuticals Co | Metodo de produccion de derivado de tienopirimidina |
| TWI744224B (zh) | 2015-02-26 | 2021-11-01 | 日商武田藥品工業股份有限公司 | 固形製劑 |
| US11306104B2 (en) * | 2018-03-14 | 2022-04-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of Relugolix |
| EP3666776A1 (en) * | 2018-12-11 | 2020-06-17 | Sandoz AG | Hydrate of a gonadotropin-releasing hormone receptor antagonist |
-
2020
- 2020-07-31 CN CN202080054641.9A patent/CN114174302A/zh active Pending
- 2020-07-31 WO PCT/US2020/044553 patent/WO2021026011A1/en not_active Ceased
- 2020-07-31 US US17/597,998 patent/US20230374030A1/en not_active Abandoned
- 2020-07-31 KR KR1020227003478A patent/KR20220047972A/ko active Pending
- 2020-07-31 JP JP2022505338A patent/JP2022542159A/ja active Pending
- 2020-07-31 EP EP20758031.7A patent/EP4007760A1/en not_active Withdrawn
- 2020-07-31 BR BR112022001002A patent/BR112022001002A2/pt not_active Application Discontinuation
- 2020-07-31 CA CA3145993A patent/CA3145993A1/en active Pending